Cambrex has announced the completion of its new facility at its Karlskoga site in Sweden that combines new laboratories for process and analytical development.
Cambrex has announced, in a June 4, 2019 press release, the completion of its new facility at its Karlskoga site in Sweden that combines new laboratories for process and analytical development.
The 600-m2 facility incorporates process technology, quality control, and analytical development laboratories, which will expand the company’s capacity and provide an area for R&D and production teams to work on scale up demonstration and tech transfer. Additionally, computer modeling will be used at the facility to optimize reactor set ups and plant conditions.
Additionally, the company reports that the lab includes high-pressure reaction vessels and crystallization equipment, which will be employed to optimize drug substance manufacturing and to expand the possible temperature range that can be used for reactions. The new quality control and analytical development labs enlarge the company’s capacity and capabilities for handling in-process and raw material analysis.
“This expansion and investments we have made at Karlskoga are part of an ongoing strategic program to ensure it has the flexibility, capacity, and capabilities to meet the evolving needs of the market and industry,” commented Bjarne Sandberg, managing director, Cambrex Karlskoga. “The new technical laboratory will act as a hub for the company’s engineers, operators, and chemists to ensure smooth scale up and handover of processes from development sites across our global network.”
This new facility, along with other recent growth seen at the site, will be supported by a new $6 million, 3000-m2 logistics center, which has already been completed and opened.
Source: Cambrex
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.